2DG-ODDA
2DG-ODDA is a 2-deoxyglucose (2-DG) (HY-13966) derivative with potent antitumor activity. 2DG-ODDA induces apoptosis, and reduces ATP production. 2DG-ODDA is taken up through both fatty acid and glucose transporters and is cleaved by α-Mannosidase (HY-P2950), releases 2DG to inhibit N-glycosylation and disrupt cellular metabolism. 2DG-ODDA inhibits tumor growth in a 4T1 mouse model. 2DG-ODDA can be used for the research of triple-negative breast cancer (TNBC).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C28H51NO10
- Masse moléculaire:561.71
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
In Vitro
2DG-ODDA (80 μM; 24 h) demonstrates significant reduction in glycolysis-based, mithochondrial and total ATP production in 4T1 TNBC cells, indicating that it disrupts mitochondrial metabolism in addition to glycolysis.[1].
2DG-ODDA (400 μM; 24 h) induces apoptosis in 4T1 TNBC cells[1].
2DG-ODDA (24 h) shows cytotoxicity in 4T1 TNBC cells with an IC50 of ~85 μM, which is a 16-fold improvement over 2DG (IC50 = ~1.34 mM)[1].
2DG-ODDA (85 μM; 24 h) is taken up through both CD36 (fatty acid transporter) and glucose transporters and is cleaved by α-Mannosidase, releasing 2DG to inhibit N-glycosylation and disrupt cellular metabolism[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:4T1 TNBC cells
-
Concentration:400 μM
-
Incubation Time:24 h
-
Result:Induced a marked increase in late-apoptotic populations.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice subcutaneously inoculated with 4T1 cells[1]
-
Dosage:7.5 mg/kg
-
Administration:s.c.; three times weekly for 2 weeks
-
Result:Significantly attenuated tumor progression, with final mean tumor volumes ~40% lower than both control groups.
Showed no treatment-related weight loss or clinical signs of adverse events.
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Annexin V plus membrane-impermeant dye apoptosis staining
- Patient-Derived Xenograft (PDX)
- Apoptosis Solutions
- Patient-Derived Orthotopic Xenograft (PDOX)
- Subcutaneous Cell-Line-Derived Xenograft
- Breast Cancer Modeling
- Orthotopic Cell-Line Xenograft
- How to Choose the Right Model Animal
Chemical Information
-
Masse moléculaire 561.71
-
Formule C28H51NO10
-
SMILES
O=C(N[C@H](CO[C@H]1O[C@H](CO)[C@@H](O)[C@@H](O)C1)C(OC)=O)CCCCCCCCCCCCCCCCC(O)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
2DG-ODDA Related Classifications
HY-179631 Related Classifications
Powered by Bioz
Keywords
- 2DG-ODDA
- Apoptosis
- ATP production
- fatty acid transport
- cytotoxic effects
- metabolic vulnerabilities
- serum albumin
- glucose transport
- mitochondrial function
- dual-transporter uptake
- apoptosis
- tumor growth suppression
- cancer therapeutic
- glycolytic inhibition
- metabolic flux analysis
- triple-negative breast cancer
- α-mannosidases
- Inhibitor
- inhibitor
- inhibit